表紙
市場調查報告書
商品編碼
822832

免疫性血小板減少性疾病相關的全球市場預測

Global Immune Thrombocytopenia (ITP) Market Research Report Forecast to 2023

出版日期: | 出版商: Market Research Future | 英文 105 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

這份報告以免疫性血小板減少性疾病(ITP)相關的全球市場為焦點,估算、預測今後交易額的轉變,並分析、考察影響其發展之推動·阻礙因素,發展機會,課題,競爭環境等要素。

第1章 報告序文

第2章 摘要整理

第3章 簡介

  • 定義
  • 調查範圍
  • 前提一覽
  • 市場結構

第4章 調查方法

  • 調查流程
  • 直接取材
  • 二次資訊收集
  • 市場規模的估算
  • 預測模式

第5章 市場動態

  • 概要
  • 推動要素
  • 阻礙因素
  • 發展機會

第6章 市場係數分析

  • 價值鏈分析
    • 研究開發及設計
    • 製造
    • 流通·銷售
    • 銷售後監測
  • 波特的五力分析
    • 賣主談判力
    • 買方議價能力
    • 新加入廠商者的威脅
    • 替代品的威脅
    • 激烈競爭

第7章 免疫性血小板減少性疾病相關的全球市場 - 各支援疾病

  • 概要
  • 急性免疫性血小板減少性疾病
  • 慢性免疫性血小板減少性疾病

第8章 免疫性血小板減少性疾病的全球市場 - 各產品類型

  • 概要
  • 皮質類固醇類
  • 促血小板生成素受體激動劑
  • 靜脈注射免疫球蛋白(IVIG)

第9章 免疫性血小板減少性疾病相關的全球市場 - 使用者

  • 概要
  • 醫院·醫院
  • 專門醫療中心
  • 研究機關·學術機構

第10章 免疫性血小板減少性疾病的全球市場 - 各地區

  • 概要
  • 北中南美
    • 北美
    • 南美
  • 歐洲
    • 西歐
    • 東歐
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 其他亞太地區
  • 中東·非洲
    • 中東
    • 非洲

第11章 競爭環境

  • 概要
  • 各企業市場佔有率分析

第12章 企業簡介

  • Amgen Inc.
  • CSL Limited
  • Dova Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • Jiangsu Hengrui Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin株式會社
  • Ligand Pharmaceuticals, Inc.
  • Novartis AG
  • Rigel Pharmaceuticals, Inc.
  • Shire
  • Shionogi Inc.(鹽野義製藥株式會社)

第13章 附錄

  • 討論的指南
目錄

Introduction

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by improper clotting of blood. ITP can cause excessive bruising and bleeding owing to the unusually low levels of platelets or thrombocytes in the blood. ITP can occur in both children and adults. ITP can be classified as primary, i.e., occurring on its own, or secondary, occurring alongside another condition. Autoimmune diseases, chronic infections, medications, pregnancy, and certain cancers are common secondary triggers of ITP. The increasing prevalence of ITP is expected to contribute to the growth of the market over the forecast period.

The global immune thrombocytopenia (ITP) market has been segmented, by type, treatment, and end user.

Based on type, the global immune thrombocytopenia (ITP) market has been categorized as acute immune thrombocytopenia and chronic immune thrombocytopenia.

On the basis of treatment, the global immune thrombocytopenia (ITP) market is further sub-segmented into corticosteroids, thrombopoietin receptor agonists, and intravenous immunoglobulins (IVIG).

Based on end user, the market has been classified as hospitals and clinics, specialty centers, and research and academic institutes.

The global immune thrombocytopenia (ITP) market was valued at USD 1,670.9 million in 2017 and is expected to register a CAGR of 5.78% during the forecast period from 2018 to 2023.

Key Players

Some of the key players in the global immune thrombocytopenia (ITP) market are: Amgen Inc., CSL Limited, Dova Pharmaceuticals, Jiangsu Hengrui Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd, Ligand Pharmaceuticals, Inc, Novartis AG, Rigel Pharmaceuticals, Inc, Shire, and Shionogi Inc.

Objectives of the Study

  • To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global immune thrombocytopenia (ITP) market
  • To provide insights into factors influencing and affecting market growth
  • To provide historical and forecast revenue of market segments and sub-segments with respect to countries
  • To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
  • To provide economic factors that influence the global immune thrombocytopenia (ITP) market
  • To provide a detailed analysis of the value chain and supply chain of the global immune thrombocytopenia (ITP) market

Target Audience

  • Research and Development (R&D) Companies
  • Academic Institutes and Universities
  • Pharmaceutical Companies
  • Raw Material Suppliers
  • Suppliers and Distributors
  • Government
  • Potential Investors

Key Findings

  • The global immune thrombocytopenia (ITP) market is expected to reach USD 2,361.2 million by 2023 at a CAGR of 5.78% from 2018 to 2023
  • Based on type, the chronic immune thrombocytopenia segment holds the largest market share and is expected to reach USD 2,036.9 million by 2023 at a CAGR of 5.94% from 2018 to 2023
  • The market in the Americas is expected to account for the largest share of the global immune thrombocytopenia (ITP) market and is projected to reach USD 1,069.8 million by 2023
  • The immune thrombocytopenia (ITP) market in Asia-Pacific is projected to be the fastest-growing at a CAGR of 4.40% from 2018 to 2023

Regional Analysis

Americas

  • North America
    • US
    • Canada

Latin America

Europe

Western Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Western Europe

Eastern Europe

Asia-Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

Middle East & Africa

  • Middle East
  • Africa

Table of Contents

1 Report Prologue

2 Executive Summary

3 Introduction

  • 3.1 Definition
  • 3.2 Scope of the Study
  • 3.3 List of Assumptions
  • 3.4 Market Structure

4 Research Methodology

  • 4.1 Research Process
  • 4.2 Primary Research
  • 4.3 Secondary Research
  • 4.4 Market Size Estimation
  • 4.5 Forecast Model

5 Market Dynamics

  • 5.1 Overview
  • 5.2 Drivers
    • 5.2.1 Rising prevalence of Immune Thrombocytopenia (ITP)
    • 5.2.2 Growing financial support by various private and government organizations
  • 5.3 Restraints
    • 5.3.1 Side effects of treatment options
    • 5.3.2 High cost of IVIG treatment
  • 5.4 Opportunities
    • 5.4.1 Emerging therapies in immune thrombocytopenia

6 Market Factor Analysis

  • 6.1 Value chain analysis
    • 6.1.1 R&D and Designing
    • 6.1.2 Manufacturing
    • 6.1.3 Distribution & Sales
    • 6.1.4 Post-Sales Monitoring
  • 6.2 Porter's Five Forces Model
    • 6.2.1 Bargaining Power of Suppliers
    • 6.2.2 Bargaining Power of Buyers
    • 6.2.3 Threat of New Entrants
    • 6.2.4 Threat of Substitutes
    • 6.2.5 Intense Rivalry

7 Global Immune Thrombocytopenia (ITP) Market by Type

  • 7.1 Overview
  • 7.2 Acute Immune Thrombocytopenia
  • 7.3 Chronic Immune Thrombocytopenia

8 Global Immune Thrombocytopenia (ITP) Market by Treatment

  • 8.1 Overview
  • 8.2 Corticosteroids
  • 8.3 Thrombopoietin receptor agonists
  • 8.4 Intravenous Immunoglobulins (IVIG)

9 Global Immune Thrombocytopenia (ITP) Market by End-user

  • 9.1 Overview
  • 9.2 Hospital & Clinics
  • 9.3 Specialty Centers
  • 9.4 Research and Academic Institutes

10 Global Immune Thrombocytopenia (ITP) Market by Region

  • 10.1 Overview
  • 10.2 Americas
    • 10.2.1 North America
      • 10.2.1.1 US
      • 10.2.1.2 Canada
    • 10.2.2 South America
  • 10.3 Europe
    • 10.3.1 Western Europe
      • 10.3.1.1 Germany
      • 10.3.1.2 France
      • 10.3.1.3 UK
      • 10.3.1.4 Italy
      • 10.3.1.5 Spain
      • 10.3.1.6 Rest of Western Europe
    • 10.3.2 Eastern Europe
  • 10.4 Asia-Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 South Korea
    • 10.4.5 Australia
    • 10.4.6 Rest of Asia-Pacific
  • 10.5 Middle East & Africa
    • 10.5.1 Middle East
    • 10.5.2 Africa

11 Competitive Landscape

  • 11.1 Overview
  • 11.2 Company Share Analysis

12 Company Profiles

  • 12.1 Amgen Inc.
    • 12.1.1 Company Overview
    • 12.1.2 Financial Overview
    • 12.1.3 Products/Services Offered
    • 12.1.4 Key Developments
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Strategy
  • 12.2 CSL Limited
    • 12.2.1 Financial Overview
    • 12.2.2 Products/Services Offered
    • 12.2.3 Key Developments
    • 12.2.4 SWOT Analysis
    • 12.2.5 Key Strategy
  • 12.3 Dova Pharmaceuticals
    • 12.3.1 Company Overview
    • 12.3.2 Financial Overview
    • 12.3.3 Products/Services Offered
    • 12.3.4 Key Developments
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Strategy
  • 12.4 F. Hoffmann-La Roche Ltd
    • 12.4.1 Company Overview
    • 12.4.2 Financial Overview
    • 12.4.3 Products/Services Offered
    • 12.4.4 Key Developments
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Strategy
  • 12.5 Jiangsu Hengrui Pharmaceutical Co., Ltd.
    • 12.5.1 Company Overview
    • 12.5.2 Financial Overview
    • 12.5.3 Products/Services Offered
    • 12.5.4 SWOT Analysis
    • 12.5.5 Key Developments
    • 12.5.6 Key strategy
  • 12.6 Kyowa Hakko Kirin Co., Ltd.
    • 12.6.1 Company Overview
    • 12.6.2 Financial Overview
    • 12.6.3 Products/Services Offered
    • 12.6.4 Key Developments
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Strategy
  • 12.7 Ligand Pharmaceuticals, Inc.
    • 12.7.1 Company Overview
    • 12.7.2 Financial Overview
    • 12.7.3 Products/Services Offered
    • 12.7.4 Key Developments
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Strategy
  • 12.8 Novartis AG
    • 12.8.1 Company Overview
    • 12.8.2 Financial Overview
    • 12.8.3 Products/Services Offered
    • 12.8.4 Key Developments
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Strategy
  • 12.9 Rigel Pharmaceuticals, Inc.
    • 12.9.1 Company Overview
    • 12.9.2 Financial Overview
    • 12.9.3 Products/Services Offered
    • 12.9.4 Key Developments
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Strategy
  • 12.1 Shire
    • 12.10.1 Company Overview
    • 12.10.2 Financial Overview
    • 12.10.3 Products/Services Offered
    • 12.10.4 Key Developments
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Strategy
  • 12.11 Shionogi Inc.
    • 12.11.1 Company Overview
    • 12.11.2 Financial Overview
    • 12.11.3 Products/Services Offered
    • 12.11.4 Key Developments
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Strategy

13 Appendix

  • 13.1 Discussion Blue Print

List of Tables

  • TABLE 1: MARKET SYNOPSIS
  • TABLE 2: LIST OF ASSUMPTIONS
  • TABLE 3: PRIMARY INTERVIEWS
  • TABLE 4: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 5: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR ACUTE ITP BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 6: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR CHRONIC ITP BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 7: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 8: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR CORTICOSTEROIDS BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 9: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR THROMBOPOIETIN RECEPTOR AGONISTS BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 10: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR INTRAVENOUS IMMUNOGLOBULINS (IVIG) BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 11: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 12: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR HOSPITAL & CLINICS BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 13: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR SPECIALTY CENTERS BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 14: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR RESEARCH AND ACADEMIC INSTITUTES BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 15: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 16: AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 17: AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 18: AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 19: AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 20: NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2015 TO 2023 (USD MILLION)
  • TABLE 21: NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 22: NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 23: NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 24: US IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 25: US IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 26: US IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 27: CANADA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 28: CANADA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 29: CANADA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 30: SOUTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 31: SOUTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 32: SOUTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 33: EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 34: EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 35: EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 36: EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 37: WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2015 TO 2023 (USD MILLION)
  • TABLE 38: WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 39: WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 40: WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 41: GERMANY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 42: GERMANY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 43: GERMANY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 44: FRANCE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 45: FRANCE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 46: FRANCE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 47: UK IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 48: UK IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 49: UK IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 50: ITALY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 51: ITALY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 52: ITALY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 53: SPAIN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 54: SPAIN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 55: SPAIN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 56: REST OF WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 57: REST OF WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 58: REST OF WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 59: EASTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 60: EASTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 61: EASTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 62: ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2015 TO 2023 (USD MILLION)
  • TABLE 63: ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 64: ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 65: ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 66: JAPAN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 67: JAPAN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 68: JAPAN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 69: CHINA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 70: CHINA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 71: CHINA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 72: INDIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 73: INDIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 74: INDIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 75: SOUTH KOREA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 76: SOUTH KOREA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 77: SOUTH KOREA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 78: AUSTRALIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 79: AUSTRALIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 80: AUSTRALIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 81: REST OF ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 82: REST OF ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 83: REST OF ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 84: MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2015 TO 2023 (USD MILLION)
  • TABLE 85: MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 86: MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 87: MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 88: MIDDLE EAST IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 89: MIDDLE EAST IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 90: MIDDLE EAST IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)
  • TABLE 91: AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2015 TO 2023 (USD MILLION)
  • TABLE 92: AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2015 TO 2023 (USD MILLION)
  • TABLE 93: AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2015 TO 2023 (USD MILLION)

List of Figures

  • FIGURE 1: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET: MARKET STRUCTURE
  • FIGURE 2: RESEARCH PROCESS
  • FIGURE 3: TOP-DOWN & BOTTOM-UP APPROACH
  • FIGURE 4: MARKET DYNAMICS: ANALYSIS OF THE GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET
  • FIGURE 5: VALUE CHAIN: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET
  • FIGURE 6: PORTER'S FIVE FORCES ANALYSIS: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET
  • FIGURE 7: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2017 & 2023 (USD MILLION)
  • FIGURE 8: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2017 & 2023 (USD MILLION)
  • FIGURE 9: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2017 & 2023 (USD MILLION)
  • FIGURE 10: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2017 & 2023 (USD MILLION)
  • FIGURE 11: AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2017 (%)
  • FIGURE 12: NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2017 (%)
  • FIGURE 13: EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2017 (%)
  • FIGURE 14: WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2017 (%)
  • FIGURE 15: ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2017 (%)
  • FIGURE 16: MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2017 (%)
  • FIGURE 17: COMPANY SHARE ANALYSIS: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET, 2017 (%)